Cargando…
The therapeutic effects of silymarin for patients with glucose/lipid metabolic dysfunction: A meta-analysis
BACKGROUND: To comprehensively evaluate the treatment efficacy and safety of silymarin for patients with glucose/lipid metabolic dysfunction using a meta-analysis. METHODS: A systematic literature search in PubMed, EMBASE and Cochrane Library databases was performed up to October 1, 2019. STATA 13.0...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7535778/ https://www.ncbi.nlm.nih.gov/pubmed/33019400 http://dx.doi.org/10.1097/MD.0000000000022249 |
_version_ | 1783590457671942144 |
---|---|
author | Xiao, Fengyan Gao, Feng Zhou, Shengxue Wang, Lina |
author_facet | Xiao, Fengyan Gao, Feng Zhou, Shengxue Wang, Lina |
author_sort | Xiao, Fengyan |
collection | PubMed |
description | BACKGROUND: To comprehensively evaluate the treatment efficacy and safety of silymarin for patients with glucose/lipid metabolic dysfunction using a meta-analysis. METHODS: A systematic literature search in PubMed, EMBASE and Cochrane Library databases was performed up to October 1, 2019. STATA 13.0 software was used to estimate pooled standardized mean difference (SMD) and 95% confidence interval (95% CI). RESULTS: Sixteen studies involving 1358 patients were identified. Overall meta-analysis showed that compared with control, silymarin significantly reduced levels of fasting blood glucose (SMD: −1.27, 95% CI = [−1.78, −0.76]; P < .001), homeostatic model assessment for insulin resistance (SMD: −0.41, 95% CI = [−0.70, −0.12]; P = .005), hemoglobin A1c (SMD: −1.88, 95% CI = [−2.57, −1.20]; P < .001), total cholesterol (SMD: −1.13, 95% CI = [−1.82, −0.77]; P < .001), triglyceride (SMD: −0.37, 95% CI = [−0.69, −0.05]; P = .025), low-density lipoprotein-cholesterol (SMD: −1.30, 95% CI = [−1.93, −0.67]; P < .001), C-reactive protein (SMD: −0.63, 95% CI = [−1.01, −0.27]; P = .001), and increased high-density lipoprotein-cholesterol (SMD: 0.17, 95% CI = [0.05, 0.29]; P = .005), but had no impacts on function indicators of liver and kidney (alanine transaminase, aspartate aminotransferase, creatinine phosphokinase, creatinine) and the complication rate. Subgroup analyses indicated that insulin (which was negative in overall analysis) was significantly decreased in patients undergoing silymarin monotherapy (SMD: −2.03, 95% CI = [−3.03, −1.04]; P = .044) for more than 3 months (SMD: −0.01, 95% CI = [−0.25, −0.24]; P = .035). CONCLUSION: Supplementation of silymarin may be effective and safe for the management of diabetes mellitus and hyperlipidemia. |
format | Online Article Text |
id | pubmed-7535778 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-75357782020-10-14 The therapeutic effects of silymarin for patients with glucose/lipid metabolic dysfunction: A meta-analysis Xiao, Fengyan Gao, Feng Zhou, Shengxue Wang, Lina Medicine (Baltimore) 3800 BACKGROUND: To comprehensively evaluate the treatment efficacy and safety of silymarin for patients with glucose/lipid metabolic dysfunction using a meta-analysis. METHODS: A systematic literature search in PubMed, EMBASE and Cochrane Library databases was performed up to October 1, 2019. STATA 13.0 software was used to estimate pooled standardized mean difference (SMD) and 95% confidence interval (95% CI). RESULTS: Sixteen studies involving 1358 patients were identified. Overall meta-analysis showed that compared with control, silymarin significantly reduced levels of fasting blood glucose (SMD: −1.27, 95% CI = [−1.78, −0.76]; P < .001), homeostatic model assessment for insulin resistance (SMD: −0.41, 95% CI = [−0.70, −0.12]; P = .005), hemoglobin A1c (SMD: −1.88, 95% CI = [−2.57, −1.20]; P < .001), total cholesterol (SMD: −1.13, 95% CI = [−1.82, −0.77]; P < .001), triglyceride (SMD: −0.37, 95% CI = [−0.69, −0.05]; P = .025), low-density lipoprotein-cholesterol (SMD: −1.30, 95% CI = [−1.93, −0.67]; P < .001), C-reactive protein (SMD: −0.63, 95% CI = [−1.01, −0.27]; P = .001), and increased high-density lipoprotein-cholesterol (SMD: 0.17, 95% CI = [0.05, 0.29]; P = .005), but had no impacts on function indicators of liver and kidney (alanine transaminase, aspartate aminotransferase, creatinine phosphokinase, creatinine) and the complication rate. Subgroup analyses indicated that insulin (which was negative in overall analysis) was significantly decreased in patients undergoing silymarin monotherapy (SMD: −2.03, 95% CI = [−3.03, −1.04]; P = .044) for more than 3 months (SMD: −0.01, 95% CI = [−0.25, −0.24]; P = .035). CONCLUSION: Supplementation of silymarin may be effective and safe for the management of diabetes mellitus and hyperlipidemia. Lippincott Williams & Wilkins 2020-10-02 /pmc/articles/PMC7535778/ /pubmed/33019400 http://dx.doi.org/10.1097/MD.0000000000022249 Text en Copyright © 2020 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nc/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc/4.0 |
spellingShingle | 3800 Xiao, Fengyan Gao, Feng Zhou, Shengxue Wang, Lina The therapeutic effects of silymarin for patients with glucose/lipid metabolic dysfunction: A meta-analysis |
title | The therapeutic effects of silymarin for patients with glucose/lipid metabolic dysfunction: A meta-analysis |
title_full | The therapeutic effects of silymarin for patients with glucose/lipid metabolic dysfunction: A meta-analysis |
title_fullStr | The therapeutic effects of silymarin for patients with glucose/lipid metabolic dysfunction: A meta-analysis |
title_full_unstemmed | The therapeutic effects of silymarin for patients with glucose/lipid metabolic dysfunction: A meta-analysis |
title_short | The therapeutic effects of silymarin for patients with glucose/lipid metabolic dysfunction: A meta-analysis |
title_sort | therapeutic effects of silymarin for patients with glucose/lipid metabolic dysfunction: a meta-analysis |
topic | 3800 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7535778/ https://www.ncbi.nlm.nih.gov/pubmed/33019400 http://dx.doi.org/10.1097/MD.0000000000022249 |
work_keys_str_mv | AT xiaofengyan thetherapeuticeffectsofsilymarinforpatientswithglucoselipidmetabolicdysfunctionametaanalysis AT gaofeng thetherapeuticeffectsofsilymarinforpatientswithglucoselipidmetabolicdysfunctionametaanalysis AT zhoushengxue thetherapeuticeffectsofsilymarinforpatientswithglucoselipidmetabolicdysfunctionametaanalysis AT wanglina thetherapeuticeffectsofsilymarinforpatientswithglucoselipidmetabolicdysfunctionametaanalysis AT xiaofengyan therapeuticeffectsofsilymarinforpatientswithglucoselipidmetabolicdysfunctionametaanalysis AT gaofeng therapeuticeffectsofsilymarinforpatientswithglucoselipidmetabolicdysfunctionametaanalysis AT zhoushengxue therapeuticeffectsofsilymarinforpatientswithglucoselipidmetabolicdysfunctionametaanalysis AT wanglina therapeuticeffectsofsilymarinforpatientswithglucoselipidmetabolicdysfunctionametaanalysis |